NanoVibronix logo
NanoVibronix NAOV

Annual report 2025
added 04-15-2026

report update icon

NanoVibronix Financial Statements 2011-2026 | NAOV

Annual Financial Statements NanoVibronix

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 92 K 135 K 4.83 M 1.03 M 10.5 M 19.4 M 21.6 M 23.4 M 27.5 M 9.5 M - - - -

Shares

629 K 27 K 159 K 1.42 M 1.26 M 9.34 M 6.94 M 6.45 M 4.96 M 4.58 M 1.98 M - - - -

Historical Prices

- 3.41 0.85 3.4 0.817 1.12 2.75 3.4 4.7 6 4.8 - - - -

Net Income

-18.2 M -3.7 M -3.71 M -5.45 M -14.3 M -4.32 K -5.79 M -4.15 M -4.96 M -2.83 M -2.88 M -2.65 M -1.99 M -1.28 M -723 K

Revenue

2.55 M 2.56 M 2.28 M 752 K 1.7 M 623 530 K 318 K 239 K 229 K 147 K 203 K 211 K 166 K 94 K

Cost of Revenue

2.4 M 1.05 M 746 K 585 K 925 K 409 K 249 K 158 K 88 K 88 K 49 K 93 K - - -

Gross Profit

153 K 1.51 M 1.54 M 167 K 770 K 214 281 K 160 K 151 K 141 K 98 K 110 K 120 K 116 K 65 K

Operating Income

-22.9 M -3.58 M -3.44 M -5.01 M -5.68 M -4.72 M -5.15 M -4.3 M -3.09 M -2.32 M -1.42 M -1.21 M - - -

Interest Expense

- - 135 K 347 K - 147 K 15 K - - - - - - - -

EBITDA

-22 M -3.58 M -3.44 M -5.01 M -5.68 M -4.72 K -5.15 M -4.3 M -3.09 M -2.31 M -1.42 M -1.2 M -1.1 M -765 K -672 K

Operating Expenses

23 M 5.09 M 4.97 M 5.18 M 6.45 M 4.93 K 5.43 M 4.46 M 3.24 M 2.46 M 1.52 M 1.32 M 1.23 M 890 K 747 K

General and Administrative Expenses

7.63 M 3.46 M 3.92 M 3.93 M 5.06 M 3.77 K 3.82 M 2.64 M 2.08 M 1.36 M 747 K 589 K 366 K 128 K 87 K

All numbers in USD currency

Quarterly Income Statement NanoVibronix

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

858 K 485 K 626 K 37.9 K 280 K 25.3 K 247 K 2.05 M 1.72 M 1.66 M 1.65 M 1.64 M 1.4 M 1.4 M 1.4 M 28 M 26.1 M 24.8 M 24.2 M 21.2 M 9.34 M 7.25 M 7.25 M 4.2 M 7.05 M 6.79 M 6.65 M 3.8 M 6.44 M 6.43 M 6.42 M 3.94 M 4.58 M 4.59 M 4.58 M 2.63 M 4.58 M 4.57 M 4.57 M 2.61 M 3.54 M 3.54 M 742 K 164 K 155 K 155 K 164 K - - - - - - - - - - - -

Net Income

510 K -3.97 M -2.5 M - -998 K -688 K -588 K - -727 K -1.07 M -1.1 M - -955 K -1.3 M -1.13 M - -6.68 M -216 K -4.92 M - -922 K -1.48 M -921 K - -815 K -1.11 M -2.68 M - -1.34 M -824 K -789 K - -1.6 M -849 K -877 K - -606 K -610 K -495 K - -1.04 M -434 K -630 K - -766 K -578 K -503 K - - - - - - - - - - - -

Revenue

722 K 494 K 1.02 M - 376 K 817 K 921 K - 458 K 294 K 354 K - 97 K 485 K 272 K - 499 K 318 K 103 K - 150 K 269 K 114 K - 101 K 263 K 79 K - 54 K 132 K 77 K - 65 K 52 K 52 K - 61 K 62 K 57 K - 40 K 39 K 29 K - 25 K 64 K -62 K - - - - - - - - - - - -

Cost of Revenue

533 K 529 K 656 K - 243 K 389 K 257 K - 109 K 78 K 119 K - 17 K 204 K 166 K - 271 K 110 K 26 K - 51 K 231 K 63 K - 54 K 56 K 26 K - 46 K 55 K 22 K - 22 K 18 K 16 K - 27 K 22 K 27 K - 10 K 15 K 10 K - 35 K 25 K - - - - - - - - - - - - -

Gross Profit

189 K -35 K 369 K - 133 K 428 K 664 K - 349 K 216 K 235 K - 80 K 281 K 106 K - 228 K 208 K 77 K - 99 K 38 K 51 K - 47 K 207 K 53 K - 8 K 77 K 55 K - 43 K 34 K 36 K - 34 K 40 K 30 K - 30 K 24 K 19 K - -10 K 39 K -40 K - - - - - - - - - - - -

Operating Income

-2.25 M -3.98 M -1.85 M - -970 K -674 K -568 K - -670 K -1.01 M -1.06 M - -924 K -1.27 M -1.11 M - -868 K -991 K -1.31 M - -804 K -1.47 M -907 K - -793 K -896 K -2.22 M - -1.33 M -825 K -790 K - -613 K -660 K -802 K - -545 K -456 K -474 K - -338 K -315 K -311 K - -518 K -268 K 144 K - - - - - - - - - - - -

Interest Expense

- 144 K 53 K - 33 K 34 K 34 K - 35 K 33 K 34 K - - -18 K - - - 1 K - - 123 K - - - - - 7 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -1.83 M - - - - - - - -1.05 M - -923 K -1.27 M -1.11 M - -867 K -990 K -1.31 M - -802 K -1.47 M -906 K - -790 K -894 K -2.22 M - -1.32 M -822 K -788 K - -607 K -655 K -801 K - -539 K -452 K -472 K - -331 K -310 K -309 K - -512 K -265 K 146 K - - - - - - - - - - - -

Operating Expenses

2.44 M 3.94 M 2.22 M - 1.1 M 1.1 M 1.23 M - 1.02 M 1.22 M 1.29 M - 1 M 1.55 M 1.22 M - 1.1 M 1.2 M 1.39 M - 903 K 1.51 M 958 K - 840 K 1.1 M 2.28 M - 1.33 M 902 K 845 K - 656 K 694 K 838 K - 579 K 496 K 504 K - 368 K 339 K 330 K - 508 K 307 K -184 K - - - - - - - - - - - -

General and Administrative Expenses

1.4 M 2.25 M 1.34 M - 673 K 716 K 946 K - 796 K 963 K 1.02 M - 738 K 1.16 M 942 K - 801 K 839 K 1.02 M - 546 K 1.31 M 657 K - 533 K 682 K 1.8 M - 868 K 454 K 480 K - 387 K 424 K 593 K - 298 K 197 K 245 K - 208 K 199 K 126 K - 265 K 151 K -48 K - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements NanoVibronix NAOV
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting NanoVibronix plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 13.19 0.81 % $ 1.78 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.22 -0.31 % $ 121 M franceFrance
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.61 -0.33 % $ 38 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Globus Medical Globus Medical
GMED
$ 93.19 -0.54 % $ 12.6 B usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 11.33 1.07 % $ 321 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Electromed Electromed
ELMD
$ 26.0 - $ 220 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 2.09 -1.42 % $ 1.27 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
LENSAR LENSAR
LNSR
$ 5.28 1.34 % $ 63.1 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.25 -1.95 % $ 50.9 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 5.48 - $ 1.16 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 15.88 0.38 % $ 373 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 10.8 -0.37 % $ 387 M usaUSA
Orthofix Medical Orthofix Medical
OFIX
$ 12.29 -0.24 % $ 487 M curacaoCuracao
LivaNova PLC LivaNova PLC
LIVN
$ 63.05 -0.57 % $ 3.44 B britainBritain
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.07 -1.37 % $ 18.1 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 37.58 -0.77 % $ 1.17 B usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 55.14 0.13 % $ 1.62 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 85.43 0.09 % $ 2.97 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 83.85 0.47 % $ 49 B usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 2.42 3.03 % $ 6.71 M usaUSA
MiMedx Group MiMedx Group
MDXG
$ 3.35 0.3 % $ 495 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 328.23 -0.24 % $ 125 B usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 23.83 -1.69 % $ 545 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.82 2.51 % $ 38.5 M usaUSA